Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
OCX 
OncoCyte Corp (OCX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/22/2025: OCX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -22.24% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/22/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 96.95M USD | Price to earnings Ratio - | 1Y Target Price 4.42 |
Price to earnings Ratio - | 1Y Target Price 4.42 | ||
Volume (30-day avg) 66083 | Beta 0.98 | 52 Weeks Range 1.92 - 4.75 | Updated Date 04/25/2025 |
52 Weeks Range 1.92 - 4.75 | Updated Date 04/25/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.66 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Revenue by Geography
Earnings Date
Report Date 2025-04-10 | When Before Market | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -364.94% |
Management Effectiveness
Return on Assets (TTM) -26.42% | Return on Equity (TTM) -910.86% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 91979576 | Price to Sales(TTM) 51.54 |
Enterprise Value 91979576 | Price to Sales(TTM) 51.54 | ||
Enterprise Value to Revenue 48.9 | Enterprise Value to EBITDA -1.25 | Shares Outstanding 28599300 | Shares Floating 10435879 |
Shares Outstanding 28599300 | Shares Floating 10435879 | ||
Percent Insiders 22.03 | Percent Institutions 48.11 |
Analyst Ratings
Rating 3.33 | Target Price 4.12 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
OncoCyte Corp
Company Overview
History and Background
OncoCyte Corporation was founded in 2009, focusing on developing non-invasive liquid biopsy tests for early cancer detection. It has evolved through strategic acquisitions and product development to expand its diagnostic offerings.
Core Business Areas
- DetermaRx: DetermaRx is a proprietary test designed to predict response to chemotherapy in early-stage lung cancer patients.
- DetermaIO: DetermaIO is a test to predict response to immune checkpoint inhibitors.
Leadership and Structure
The leadership team includes key executives in areas such as clinical development, commercial operations, and finance. The organizational structure includes departments for research and development, commercialization, and operations.
Top Products and Market Share
Key Offerings
- DetermaRx: DetermaRx predicts chemotherapy response in early-stage lung cancer. Market share data is not readily available. Key competitors include companies offering similar predictive biomarkers for lung cancer treatment decisions. Competitors include companies offering genomic tests for lung cancer treatment selection.
- DetermaIO: DetermaIO predicts response to immune checkpoint inhibitors. Market share data is not publicly available. Competitors offer similar assays for predicting immunotherapy response based on biomarkers. Competitors include companies offering comprehensive genomic profiling services.
Market Dynamics
Industry Overview
The diagnostic testing industry is growing, driven by advancements in genomics and personalized medicine. There is an increasing demand for non-invasive diagnostic tools for early cancer detection and treatment selection.
Positioning
OncoCyte is positioned as a developer of novel liquid biopsy tests for cancer diagnosis and treatment optimization. Its competitive advantage lies in its proprietary biomarker technologies.
Total Addressable Market (TAM)
The total addressable market for cancer diagnostics is estimated to be in the billions of dollars. OncoCyte targets specific segments within this market, focusing on lung cancer and immunotherapy prediction. The TAM for OncoCyte is estimated to be $3B.
Upturn SWOT Analysis
Strengths
- Proprietary biomarker technologies
- Focus on non-invasive liquid biopsy tests
- Potential for early cancer detection
- Strategic partnerships
Weaknesses
- Limited commercial traction
- Dependence on a few key products
- High cash burn rate
- Need for further clinical validation
Opportunities
- Expanding into new cancer types
- Securing reimbursement for tests
- Developing companion diagnostics
- Partnerships with pharmaceutical companies
Threats
- Competition from larger diagnostic companies
- Regulatory hurdles
- Changing reimbursement landscape
- Technological advancements by competitors
Competitors and Market Share
Key Competitors
- NVGN
- MOLX
- CDx
- CTMX
- THRM
Competitive Landscape
OncoCyte faces competition from established diagnostic companies with greater resources. Its advantages include its proprietary technologies and focus on specific cancer types.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by product development and strategic acquisitions.
Future Projections: Future growth is expected to be driven by increased adoption of its diagnostic tests and expansion into new markets. Analyst estimates are not included in this model.
Recent Initiatives: Recent initiatives include commercialization efforts for DetermaRx and DetermaIO and strategic partnerships.
Summary
OncoCyte Corp is a diagnostic company with proprietary technologies focused on non-invasive liquid biopsy tests for cancer. Its strengths lie in its innovative products, but it faces challenges with commercialization and competition. Future growth depends on expanding into new markets and securing reimbursement. The company needs to carefully manage its cash burn rate and navigate the competitive landscape.
Similar Companies
CDX
Simplify Exchange Traded Funds
CDX
Simplify Exchange Traded Funds
CTMX
CytomX Therapeutics Inc
CTMX
CytomX Therapeutics Inc
THRM
Gentherm Inc
THRM
Gentherm Inc
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market share data is estimates based on available information and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About OncoCyte Corp
Exchange NASDAQ | Headquaters Irvine, CA, United States | ||
IPO Launch date 2016-01-04 | President, CEO & Director Mr. Joshua Riggs | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 46 | Website https://www.oncocyte.com |
Full time employees 46 | Website https://www.oncocyte.com | ||
OncoCyte Corporation operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The company also offers VitaGraft Kidney, a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA for kidney transplantation; VitaGraft Liver, a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA for liver transplantation; and GraftAssure, a dd-cfDNA test that uses droplet digital PCR technology to measure the concentration of dd-cfDNA using 48 predefined SNPs. In addition, it provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. for the development and commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.